Archive - Cancer Currents Blog
- After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought
In everyday medical care, there may be more complications from invasive diagnostic procedures performed after lung cancer screening than has been reported in large studies.
- Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice
Researchers have found an unconventional way to unleash the immune system against liver cancer in mice. The researchers used an investigational drug to curb the production of a checkpoint inhibitor protein that shields tumors from the immune system.
- Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma
FDA has approved pembrolizumab (Keytruda) to treat people with Merkel cell carcinoma, a rare and deadly form of skin cancer. The approval covers use of the drug to treat locally advanced or metastatic forms of the disease.
- Glioblastoma Study Highlights Sex Differences in Brain Cancer
Men and women with glioblastoma appear to respond differently to standard treatment. A new study identifies biological factors that might contribute to this sex difference.
- African American Men More Likely to Die from Low-Grade Prostate Cancer
For African American men, the risk of dying from low-grade prostate cancer is double that of men of other races, a new study has found. But, despite the increase, the risk is still small.
- Managing Cancer Pain: Are Better Approaches on the Horizon?
Pain is a common and much-feared symptom among people with cancer and long-term survivors. As more people survive cancer for longer periods, there is a renewed interest in developing new, nonaddictive approaches for managing their chronic pain.
- Immunotherapy Effective in Alveolar Soft Part Sarcoma
People with advanced alveolar soft part sarcoma (ASPS), a rare cancer, appear to benefit from a type of immunotherapy called an immune checkpoint inhibitor, according to results from a small clinical trial.
- Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer
On December 6, 2018, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a standard three-drug regimen as an initial treatment for advanced lung cancer that does not have EGFR or ALK mutations.
- For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target
A new study has identified a potential biomarker of early-stage non–small cell lung cancer (NSCLC). The biomarker, the study’s leaders said, could help diagnose precancerous lung growths and early-stage lung cancers noninvasively and distinguish them from noncancerous growths.
- FDA Approvals Bring New Options for Older Patients with AML
FDA has approved venetoclax (Venclexta) and glasdegib (Daurismo) for use in people with acute myeloid leukemia aged 75 and older and those with health conditions that prevent them from receiving the intensive chemotherapy regimen that is the standard initial treatment.
- The HPV Vaccine: Increasing the Use of an Important Cancer Prevention Tool
Dr. Barbara Rimer, chair of the President’s Cancer Panel, summarizes the panel’s recent report on the HPV vaccine, which includes priorities and strategies to ensure that more people receive this critical cancer vaccine.
- Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning
In women with early-stage breast cancer, two clinical trials have shown that both whole- and partial-breast radiation therapy are effective at preventing the cancer from returning after breast-conserving surgery.
- Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells
Two new studies show how the drugs venetoclax (Venclexta) and azacitidine (Vidaza) team up to block the unique metabolism of leukemia stem cells and may explain why the drug combination is effective against acute myeloid leukemia.
- Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows
In the largest-ever randomized trial testing vitamin D for cancer prevention, the supplement did not lower the risk of developing cancer. The Vitamin D and Omega-3 Trial (VITAL) includes a nationally representative sample of nearly 26,000 participants.
- Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival
In an early-phase trial, dabrafenib plus trametinib shrank tumors in patients with biliary tract cancer and adenocarcinoma of the small intestine whose tumors had a specific mutation in the BRAF gene.
- Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery
The test measures genomic changes in thyroid biopsy samples and generates a score based on how strongly each change is associated with thyroid cancer. A study showed the test accurately identified samples that, after surgery, were found to be benign.
- Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function
Results from a clinical trial suggest that, in patients with brain metastases, an advanced radiotherapy technique limits harm to patients’ cognitive function without affecting the treatment’s effect on tumors.